SMITH & NEPHEW PLC Smith & Nephew plc Share Price Mexican S.E.
Equities
SN1 N
GB0009223206
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 199.8 MXN | -15.42% |
|
-.--% | -7.45% |
| 05-14 | European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading | MT |
| 05-09 | SMITH & NEPHEW : Q1 24: A few positives underneath the top-line miss |  |
| Sales 2024 * | 5.82B 97.08B 458B | Sales 2025 * | 6.12B 102B 482B | Capitalization | 11.27B 188B 888B |
|---|---|---|---|---|---|
| Net income 2024 * | 541M 9.03B 42.64B | Net income 2025 * | 694M 11.58B 54.7B | EV / Sales 2024 * | 2.38 x |
| Net Debt 2024 * | 2.56B 42.65B 201B | Net Debt 2025 * | 2.23B 37.21B 176B | EV / Sales 2025 * | 2.21 x |
| P/E ratio 2024 * |
21.9
x | P/E ratio 2025 * |
16.8
x | Employees | 18,452 |
| Yield 2024 * |
2.96% | Yield 2025 * |
3.32% | Free-Float | 99.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on Smith & Nephew plc
More recommendations
More press releases
More news
| 1 day | -15.42% | ||
| 3 months | -7.45% | ||
| 6 months | -7.45% | ||
| Current year | -7.45% |
Current year
199.78
236.21
1 year
199.78236.21
3 years
199.78437.25
5 years
199.78440.50
10 years
199.78440.50
| Managers | Title | Age | Since |
|---|---|---|---|
Deepak Nath
CEO | Chief Executive Officer | - | 31/03/22 |
John Rogers
DFI | Director of Finance/CFO | 56 | 11-30 |
Alison Parkes
CMP | Compliance Officer | - | 31/03/99 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marc E. Owen
BRD | Director/Board Member | 65 | 30/09/17 |
Jeremy Maiden
BRD | Director/Board Member | 62 | 13/09/23 |
Rupert Soames
CHM | Chairman | 63 | 25/04/23 |
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipment. Net sales break down by activity sector as follows:
- orthopedic surgery (39.9%): primarily orthopedic implants (hips, knees and shoulders);
- sports medicine, arthroscopy and cervicofacial surgery (31.2%): surgery and damaged tissue repair products and instruments, visualization products, etc.;
- wound care (28.9%): skin grafts for major burns victims, treatments for leg ulcers, etc.
The United States accounts for 53.7% of net sales.
Calendar
24/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
12.92
USD
Average target price
16.35
USD
Spread / Average Target
+26.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.86% | 124B | |
| +4.17% | 9.17B | |
| -21.47% | 4.71B | |
| +8.77% | 3.44B | |
| -6.03% | 2.88B | |
| -12.05% | 2.11B | |
| -7.83% | 2.09B | |
| -22.84% | 1.8B | |
| -8.57% | 1.17B |
- Stock Market
- Equities
- SN. Stock
- SN1 N Stock
